-- 周二，由于美伊和平谈判陷入僵局，原油价格上涨，美国股市收低。 * 美国总统唐纳德·特朗普在接受CNBC采访时表示，他预计美国和伊朗将达成一项“伟大的协议”，指的是拟议在伊斯兰堡举行的第二轮会谈，但伊朗尚未确认是否会出席。 * 据《华尔街日报》报道，伊朗已告知地区调解人，将于周二派遣谈判小组前往伊斯兰堡。 * 美国3月份零售销售额增长1.7%，高于2月份修正后的0.7%的增幅，也高于彭博社调查预期的1.4%的增幅。 * 美国全国房地产经纪人协会表示，3月份待售房屋销售量增长1.5%，高于彭博社调查预期的0.5%的增幅，也高于2月份的2.5%增幅。销售额较2025年3月下降1.1%。 * 5月西德克萨斯中质原油期货价格上涨3.93美元，收于每桶91.35美元；全球基准布伦特原油期货价格上涨5.29美元，收于每桶100.77美元。 * 北方信托(NTRS)股价上涨8%，成为标普500指数中涨幅最大的股票，此前该公司公布的第一季度盈利和营收均高于预期。 * 农机用品公司(TSCO)股价下跌12%，成为标普500指数中跌幅最大的股票，此前该公司公布的第一季度业绩不及市场预期，其宠物用品业务表现低于平均水平。
Related Articles
Asia
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
$KOSDAQ:440110
Asia
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.
$BOM:524715$NSE:SUNPHARMA